JP6458270B2 - 置換されたヒドロキサム酸化合物 - Google Patents

置換されたヒドロキサム酸化合物 Download PDF

Info

Publication number
JP6458270B2
JP6458270B2 JP2016534884A JP2016534884A JP6458270B2 JP 6458270 B2 JP6458270 B2 JP 6458270B2 JP 2016534884 A JP2016534884 A JP 2016534884A JP 2016534884 A JP2016534884 A JP 2016534884A JP 6458270 B2 JP6458270 B2 JP 6458270B2
Authority
JP
Japan
Prior art keywords
alkyl
alkoxy
compound
heteroaryl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016534884A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016535758A (ja
JP2016535758A5 (enExample
Inventor
ジョウ ペイ
ジョウ ペイ
ジェイ．トゥーン エリック
ジェイ．トゥーン エリック
エー．ニコラス ロバート
エー．ニコラス ロバート
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Duke University
Original Assignee
University of North Carolina at Chapel Hill
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill, Duke University filed Critical University of North Carolina at Chapel Hill
Publication of JP2016535758A publication Critical patent/JP2016535758A/ja
Publication of JP2016535758A5 publication Critical patent/JP2016535758A5/ja
Application granted granted Critical
Publication of JP6458270B2 publication Critical patent/JP6458270B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
JP2016534884A 2013-08-16 2014-08-18 置換されたヒドロキサム酸化合物 Expired - Fee Related JP6458270B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361866823P 2013-08-16 2013-08-16
US61/866,823 2013-08-16
US201361867933P 2013-08-20 2013-08-20
US61/867,933 2013-08-20
PCT/US2014/051459 WO2015024010A2 (en) 2013-08-16 2014-08-18 Substituted hydroxamic acid compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018224004A Division JP2019077688A (ja) 2013-08-16 2018-11-29 置換されたヒドロキサム酸化合物

Publications (3)

Publication Number Publication Date
JP2016535758A JP2016535758A (ja) 2016-11-17
JP2016535758A5 JP2016535758A5 (enExample) 2017-09-28
JP6458270B2 true JP6458270B2 (ja) 2019-01-30

Family

ID=52468825

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016534884A Expired - Fee Related JP6458270B2 (ja) 2013-08-16 2014-08-18 置換されたヒドロキサム酸化合物
JP2018224004A Pending JP2019077688A (ja) 2013-08-16 2018-11-29 置換されたヒドロキサム酸化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018224004A Pending JP2019077688A (ja) 2013-08-16 2018-11-29 置換されたヒドロキサム酸化合物

Country Status (6)

Country Link
US (1) US10647664B2 (enExample)
EP (1) EP3041354A4 (enExample)
JP (2) JP6458270B2 (enExample)
AU (1) AU2014306451B2 (enExample)
CA (1) CA2921427A1 (enExample)
WO (1) WO2015024010A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019077688A (ja) * 2013-08-16 2019-05-23 デューク ユニバーシティ 置換されたヒドロキサム酸化合物

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9796686B2 (en) 2014-05-16 2017-10-24 Idorsia Pharmaceuticals Ltd Antibacterial quinazoline-4(3H)-one derivatives
ES2909122T3 (es) 2015-11-09 2022-05-05 Forge Therapeutics Inc Compuestos a base de hidroxipiridinona e hidroxipirimidinona para el tratamiento de infecciones bacterianas
EP3374355A4 (en) 2015-11-09 2019-04-17 Forge Therapeutics, Inc. COMPOUNDS BASED ON PYRONE AND METHOD FOR THE TREATMENT OF BACTERIAL INFECTIONS
US11034649B2 (en) 2016-04-25 2021-06-15 Duke University Benzoylglycine derivatives and methods of making and using same
CN110072844B (zh) 2016-12-23 2023-06-02 英特维特国际股份有限公司 用于治疗溶血曼海姆菌或睡眠嗜组织菌感染的化合物
US11021471B2 (en) 2017-05-10 2021-06-01 Forge Therapeutics, Inc. Antibacterial compounds
SG11202007665RA (en) * 2018-02-10 2020-09-29 Kbp Biosciences Co Ltd Compound acting as antibiotics
CA3113226A1 (en) * 2018-09-20 2020-03-26 Forge Therapeutics, Inc. Antibacterial compounds
WO2021195260A1 (en) 2020-03-25 2021-09-30 Forge Therapeutics, Inc. Lpxc inhibitor and methods of making
DK4210700T3 (da) 2020-09-09 2025-09-08 Crinetics Pharmaceuticals Inc Formuleringer af en somatostatinmodulator
WO2023055686A1 (en) 2021-09-28 2023-04-06 Blacksmith Medicines, Inc. Lpxc inhibitors and uses thereof
WO2024077160A2 (en) * 2022-10-05 2024-04-11 Duke University Compositions comprising prodrugs of hydroxyamate-based compounds and methods of making and using same

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993014077A1 (en) 1992-01-21 1993-07-22 Glaxo Group Limited Piperidineacetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation
TW448172B (en) 1996-03-08 2001-08-01 Pharmacia & Upjohn Co Llc Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation
US5925659A (en) 1996-05-07 1999-07-20 Merck & Co., Inc. Antibacterial agents
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
JP2000344752A (ja) * 1999-04-01 2000-12-12 Sumitomo Pharmaceut Co Ltd 点眼剤
US6511993B1 (en) 1999-06-03 2003-01-28 Kevin Neil Dack Metalloprotease inhibitors
PL207295B1 (pl) * 2002-01-29 2010-11-30 Serono Lab Podstawione pochodne metylenoamidowe , ich zastosowanie i sposób ich wytwarzania oraz kompozycja farmaceutyczna
BR0309671A (pt) 2002-04-25 2005-05-03 Pharmacia Corp ácidos de piperidinil- e piperazinil-sulfonilmetil hidroxâmicos e seu uso como inibidores de protease
KR101011373B1 (ko) 2002-07-11 2011-01-28 비큐론 파마슈티컬스 인코포레이티드 항균작용을 갖는 ｎ-히드록시아미드 유도체
ES2552247T3 (es) * 2003-01-08 2015-11-26 The University Of Washington Agentes antibacterianos
US20050154022A1 (en) 2004-01-14 2005-07-14 H. Lundbeck A/S 4-aryl piperidines
US7638513B2 (en) 2004-06-02 2009-12-29 Schering Corporation Compounds for the treatment of inflammatory disorders
AT502219B1 (de) 2005-08-04 2007-04-15 Sanochemia Pharmazeutika Ag Verfahren zur reindarstellung von 5-substituierten tetrazolen
EP1957449A1 (en) 2005-12-01 2008-08-20 Schering Corporation Compounds for the treatment of inflammatory disorders and microbial diseases
CN101528711A (zh) 2006-08-31 2009-09-09 先灵公司 可用作抗细菌剂的乙内酰脲衍生物
WO2008105515A1 (ja) 2007-02-28 2008-09-04 Taisho Pharmaceutical Co., Ltd. 新規なヒドロキサム酸誘導体
CN101765585B (zh) 2007-06-12 2017-03-15 尔察祯有限公司 抗菌剂
JP2011525927A (ja) 2008-06-25 2011-09-29 シェーリング コーポレイション 複素環式抗菌剤の合成および使用
CA2732045A1 (en) 2008-08-04 2010-02-11 Schering Corporation Urea derivatives as antibacterial agents
JP5455913B2 (ja) 2008-08-27 2014-03-26 大正製薬株式会社 ナフチリジン−ｎ−オキシドを有する新規ヒドロキサム酸誘導体
US8372885B2 (en) * 2008-09-17 2013-02-12 Novartis Ag Organic compounds and their uses
WO2010100475A1 (en) 2009-03-02 2010-09-10 Astrazeneca Ab Hydroxamic acid derivatives as gram-negative antibacterial agents
WO2011005355A1 (en) 2009-05-07 2011-01-13 Achaogen, Inc. Combinations comprising a lpxc inhibitor and an antibiotic for use in the treatment of infections caused by gram-negative bacteria
CA2774250C (en) 2009-10-13 2013-12-17 Pfizer Inc. C-linked hydroxamic acid derivatives useful as antibacterial agents
US8389536B2 (en) 2009-10-27 2013-03-05 Hoffmann-La Roche Inc. Positive allosteric modulators (PAM)
SI2512474T1 (sl) 2009-12-16 2014-12-31 Pfizer Inc. N-vezani derivati hidroksamske kisline, uporabni kot protibakterijska sredstva
SMT201900482T1 (it) * 2010-04-20 2019-09-09 Fujifilm Toyama Chemical Co Ltd Derivato dell'acido idrossammico
US9738604B2 (en) * 2010-09-03 2017-08-22 Duke University Ethynylbenzene derivatives
US8772300B2 (en) * 2011-04-19 2014-07-08 Hoffmann-La Roche Inc. Phenyl or pyridinyl-ethynyl derivatives
WO2013049255A1 (en) * 2011-09-26 2013-04-04 Vanderbilt University Substitued 5-(prop-1-yn-1-yl)picolinamide analogs as allosteric modulators of mglur5 receptors
JP6006609B2 (ja) * 2011-10-19 2016-10-12 大正製薬株式会社 新規なヒドロキサム酸誘導体を含有する医薬
WO2013170165A1 (en) * 2012-05-10 2013-11-14 Achaogen, Inc. Antibacterial agents
SI2975022T1 (sl) * 2013-03-15 2019-08-30 Fujifilm Toyama Chemical Co., Ltd. Novi derivati hidroksamske kisline ali soli le-teh
WO2015024010A2 (en) * 2013-08-16 2015-02-19 Duke University Substituted hydroxamic acid compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019077688A (ja) * 2013-08-16 2019-05-23 デューク ユニバーシティ 置換されたヒドロキサム酸化合物

Also Published As

Publication number Publication date
EP3041354A2 (en) 2016-07-13
EP3041354A4 (en) 2017-06-14
WO2015024010A2 (en) 2015-02-19
AU2014306451A1 (en) 2016-03-03
JP2016535758A (ja) 2016-11-17
WO2015024010A3 (en) 2015-04-16
AU2014306451B2 (en) 2019-01-17
JP2019077688A (ja) 2019-05-23
US20160221934A1 (en) 2016-08-04
CA2921427A1 (en) 2015-02-19
US10647664B2 (en) 2020-05-12

Similar Documents

Publication Publication Date Title
JP6458270B2 (ja) 置換されたヒドロキサム酸化合物
RU2712275C9 (ru) Замещенные полициклические производные пиридона и их пролекарства
US10597361B2 (en) Ethynylbenzene derivatives
RU2745071C2 (ru) Лекарственный препарат для лечения гриппа, характеризующийся тем, что в нем объединены ингибитор кэп-зависимой эндонуклеазы и лекарственное средство против гриппа
WO2018030463A9 (ja) 置換された多環性ピリドン誘導体およびそのプロドラッグを含有する医薬組成物
US9908851B2 (en) 2-piperidinyl substituted N,3-dihydroxybutanamides
US20240425447A1 (en) Benzoylglycine derivatives and methods of making and using same
JP2016505597A (ja) Ｐｒｍｔ５阻害剤およびその使用
RS64012B1 (sr) Derivati supstituisanog policikličnog piridona i njihov prolek
US10189786B2 (en) Antibacterial compounds
WO2007149782A2 (en) Selective inhibitors for transferases
HK40104425A (en) Benzoylglycine derivatives and methods of making and using same
WO2024071371A1 (ja) 複素環式化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170818

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170818

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180807

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181030

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20181127

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20181127

R150 Certificate of patent or registration of utility model

Ref document number: 6458270

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees